Generation of bPIV3-vectored PIV and RSV Vaccines

bPIV3 载体 PIV 和 RSV 疫苗的生成

• 批准号: 6337217
• 负责人: AURELIA A HALLER
• 金额: $ 60.23万
• 依托单位: MEDIMMUNE VACCINES, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-04 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6337217
• 关键词: Cercopithecidae; Macaca mulatta; Paramyxovirus; active immunization; attenuated microorganism; biotechnology; drug screening /evaluation; genetic manipulation; hamsters; laboratory rat; live vaccine; nonhuman therapy evaluation; respiratory syncytial virus; transfection /expression vector; vaccine development; vector vaccine; virus protein

DESCRIPTION: (Adapted from Applicant's Abstract) Human parainfluenza virus (hPIV) and human respiratory syncytial virus (hRSV) are the main causes of acute respiratory diseases during infancy and early childhood worldwide, often requiring hospitalization. Both viruses are also responsible for serious respiratory tract infections in elderly and immunocompromised individuals. No vaccines are currently available to prevent PlV or RSV infection and disease. Aviron proposes to develop live, attenuated vaccines for prevention of disease caused by hPIV and hRSV. A novel bovine PIV3 (bPIV3) virus rescue system, using this proven safe vaccine, was established successfully at Aviron using reverse genetics. In the Phase I SBIR grant period, we used bPIV3 as a virus vector to express the hPIV3 and hRSV (subgroup A) surface glycoproteins. In phase II of the SBIR program, clinical trial material of the two vaccine candidates will be used to evaluate their attenuation, immunogenicity, and efficacy in primates. In addition, the bPIV3 vector will be employed to generate hPIV 1, 2 and hRSV subgroup B vaccines using novel molecular approaches. Our goal is to generate bPIV3-vectored vaccines for hPIV1, 2, 3 and hRSV (A and B) for human clinical trials and commercial development. PROPOSED COMMERCIAL APPLICATIONS: Aviron's goal is to produce live, attenuated hPIV and hRSV vaccines using bPIV3 as a virus vaccine vector for prevention of diseases caused by hPIV 1, 2, and 3 and hRSV(subgroups A and B) infection. These vaccines will fill a current unmet health need.

描述：（改编自申请人的摘要）人类副流感病毒 (hPIV) 和人呼吸道合胞病毒 (hRSV) 是引起该病的主要原因 全世界婴儿期和幼儿期的急性呼吸道疾病，通常 需要住院治疗。这两种病毒还造成严重的 老年人和免疫功能低下者的呼吸道感染。不 目前已有疫苗可预防 PIV 或 RSV 感染和疾病。 Aviron 建议开发减毒活疫苗来预防疾病 由 hPIV 和 hRSV 引起。一种新型牛 PIV3 (bPIV3) 病毒救援系统，使用 这种经过验证的安全疫苗是在 Aviron 使用反向成功建立的 遗传学。在第一期SBIR资助期间，我们使用bPIV3作为病毒载体 表达 hPIV3 和 hRSV（A 亚组）表面糖蛋白。在第二阶段 SBIR计划，两种候选疫苗的临床试验材料将 用于评估其在灵长类动物中的减毒作用、免疫原性和功效。 此外，bPIV3载体将用于生成hPIV 1、2和hRSV 使用新型分子方法的 B 亚组疫苗。我们的目标是产生 用于人类临床的 hPIV1、2、3 和 hRSV（A 和 B）bPIV3 载体疫苗 试验和商业开发。 拟议的商业应用： Aviron 的目标是使用 bPIV3 作为病毒疫苗载体生产 hPIV 和 hRSV 减毒活疫苗，用于预防 hPIV 1、2 和 3 以及 hRSV（A 和 B 亚型）感染引起的疾病。这些疫苗将满足当前未满足的健康需求。